Skip to main content
. 2020 Jan 27;12(2):299. doi: 10.3390/cancers12020299

Figure 2.

Figure 2

Distribution of all patients vaccinated in clinical trials with RNA-modified dendritic cells per (A) RNA source; (B) dendritic cell type and RNA loading strategy, including the number and percentage of total (n = 696), and (C) the spreading of the dendritic cell type and RNA loading strategy over time. Abbreviations: EP, electroporation; HIV-1, human immunodeficiency virus-1; iDC, immature dendritic cells; IVT, in vitro transcribed; mDC, mature dendritic cells; PP, passive pulsing; RNA, ribonucleic acid.